<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark D Siegel, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed Siemieniuk, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gordon Guyatt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ellen L Burnham, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients with acute respiratory distress syndrome (ARDS) require fluid management to optimize oxygenation and provide hemodynamic support. Several pharmacotherapies may also be needed for those who remain hypoxemic despite standard therapies targeted at ARDS (eg, glucocorticoids, neuromuscular blockers, inhaled pulmonary vasodilators). In addition, patients with ARDS require supportive therapies during their illness to reduce the rate of complications associated with ARDS and mechanical ventilation.</p><p>Fluid management, pharmacotherapy, and supportive care of the ARDS patients are discussed here. Etiologies, pathophysiology, clinical manifestations, diagnosis mechanical ventilation strategies, and novel therapies are discussed in detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1601.html" rel="external">"Acute respiratory distress syndrome: Prognosis and outcomes in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1618.html" rel="external">"Acute respiratory distress syndrome: Investigational or ineffective therapies in adults"</a>.)</p><p></p><p class="headingAnchor" id="H619420288"><span class="h1">CONSERVATIVE FLUID MANAGEMENT</span></p><p class="headingAnchor" id="H1788079783"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>Even in patients with ARDS who are not intravascularly volume overloaded, we suggest a strategy of conservative rather than liberal fluid management, provided hypotension and organ hypoperfusion can be avoided [<a href="#rid1">1-4</a>]. The rationale for a conservative strategy in patients with ARDS is based upon an increased risk of pulmonary edema and data that suggest improved oxygenation with a conservative approach, despite a lack of clear mortality benefit. (See <a class="local">'Efficacy'</a> below.)</p><p>Patients with ARDS are at increased risk of pulmonary edema. This risk is largely due to increased vascular permeability. The quantity of edema formed depends directly upon hydrostatic pressure since oncotic forces are less capable of retaining fluid within the pulmonary capillaries  (<a class="graphic graphic_figure graphicRef73684 graphicRef69933 graphicRef73443 graphicRef61194" href="/z/d/graphic/73684.html" rel="external">figure 1A-D</a>) [<a href="#rid5">5-8</a>]. (See  <a class="medical medical_review" href="/z/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a>.)</p><p class="headingAnchor" id="H1768894637"><span class="h2">Goal and fluid choice</span><span class="headingEndMark"> — </span>The overall goal is to minimize or eliminate a positive fluid balance. It is reasonable to target a central venous pressure (CVP) of &lt;4 mmHg or, if a pulmonary artery catheter is in place, a pulmonary artery occlusion pressure (PAOP) &lt;8 mmHg. Diuretics, in addition to fluid restriction, may need to be administered to achieve this goal. However, in practice, these goals may be difficult to achieve.</p><p>While fluid choice is dependent upon the type of support needed, we generally favor a crystalloid solution, such as a balanced salt solution. This choice is based upon indirect data from critically ill patients with hypovolemic or septic shock. These data are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Choice of replacement fluid'</a>.)</p><p>Point-of-care ultrasonography is being increasingly used to manage fluids in ARDS, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">"Evaluation and management of suspected sepsis and septic shock in adults", section on 'Hemodynamic'</a> and  <a class="medical medical_review" href="/z/d/html/14867.html" rel="external">"Indications for bedside ultrasonography in the critically ill adult patient"</a>.)</p><p class="headingAnchor" id="H3375477770"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Benefit from a conservative fluid strategy was best illustrated by a trial in which 1000 patients with ARDS were randomly assigned to seven days of either a conservative strategy (CVP &lt;4 mmHg or PAOP &lt;8 mmHg) or a liberal strategy (CVP of 10 to 14 mmHg or PAOP of 14 to 18 mmHg) [<a href="#rid1">1</a>]. <a class="drug drug_general" data-topicid="8482" href="/z/d/drug information/8482.html" rel="external">Furosemide</a> or intravenous fluids were given to meet intravascular pressure targets, as long as patients were hemodynamically stable; hemodynamic stability was defined by a mean arterial blood pressure &gt;60 mmHg without the use of vasopressors, a urine output of at least 0.5 mL per kilogram of body weight per hour, and evidence of adequate circulation based on physical examination or a cardiac index of at least 2.5 L per minute per square meter of body-surface area. The conservative strategy improved the oxygenation index (see  <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia", section on 'Oxygenation index'</a>) and lung injury score and increased the number of ventilator-free days (15 versus 12 days) and ICU-free days (13 versus 11 days). The 60-day mortality rate was no different between the groups. Despite a mean cumulative fluid balance of -136 mL in the conservative strategy group compared with +6992 mL in the liberal strategy group, the mean CVP and PAOP remained well above the target goals in the conservative management group, suggesting that conservative targets are difficult to achieve.</p><p class="bulletIndent1">Retrospective data suggest a possible improvement in mortality with conservative fluid management. A post-hoc analysis of the trial above [<a href="#rid1">1</a>] suggested a mortality benefit only among those with an initial CVP ≤8 mmHg [<a href="#rid9">9</a>]. In another large retrospective study of critically ill patients, a positive fluid balance on day 3 was associated with increased 30-day mortality (odds ratio 1.26) whereas a negative fluid balance was associated with lower mortality [<a href="#rid8">8</a>].</p><p></p><p>Other long-term outcomes are poorly studied. A post-hoc analysis of the trial above [<a href="#rid1">1</a>] suggested a possible association between conservative fluid management and cognitive impairment in ARDS survivors [<a href="#rid3">3</a>].</p><p>Preliminary work suggests that specific subsets of ARDS patients with higher levels of systemic inflammation may be more likely to benefit from conservative fluid management [<a href="#rid10">10</a>]. However, further studies are warranted to explore the relationship between fluid management strategies and long-term outcomes in specific ARDS subpopulations.</p><p class="headingAnchor" id="H2523201667"><span class="h1">PARALYSIS (NEUROMUSCULAR BLOCKADE)</span></p><p class="headingAnchor" id="H4285673812"><span class="h2">Our approach</span><span class="headingEndMark"> — </span>We suggest <strong>not routinely</strong> administering neuromuscular blockers (NMBs) to patients with ARDS. This approach is based upon a lack of robust evidence to support meaningful benefit in patients with ARDS and the potential for harm. While data are limited, we reserve their use for a limited number patients with ARDS who have severe hypoxemia refractory to standard therapies and patients with severe ventilator dyssynchrony that is refractory to ventilator adjustment and sedation, particularly if it leads to double triggering (eg, unwanted motor movements, such as shivering due to hypothermia)  (<a class="graphic graphic_table graphicRef75880" href="/z/d/graphic/75880.html" rel="external">table 1</a>). Indications and administration of NMBs are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1590.html" rel="external">"Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects"</a>.)</p><p class="headingAnchor" id="H1944338022"><span class="h2">Efficacy</span><span class="headingEndMark"> — </span>Data that support this approach include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In the first multicenter trial (ACURASYS; 2010), 340 patients with moderate or severe ARDS (arterial oxygen tension/fraction of inspired oxygen [PaO<sub>2</sub>/FiO<sub>2</sub>] ratio of &lt;150 mmHg) on low tidal volume mechanical ventilation were randomly assigned to receive <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">cisatracurium</a> besylate or placebo by continuous infusion for 48 hours [<a href="#rid11">11</a>]. Both groups were deeply sedated to a Ramsay sedation score of 6 (no response to glabellar tap). Cisatracurium did not lower the crude 90-day, 28-day, hospital, or ICU mortality rates compared with placebo but did decrease the adjusted 90-day mortality in patients with severe ARDS (ie, PaO<sub>2</sub>/FiO<sub>2</sub> ratio &lt;120 mmHg; hazard ratio 0.68, 95% CI 0.48-0.98). Patients treated with cisatracurium besylate also had significantly more ventilator-free days during the first 28 and 90 days and were significantly less likely to experience barotrauma. There was no difference in the frequency of intensive care unit (ICU) acquired neuromuscular weakness.</p><p></p><p class="bulletIndent1">Despite this encouraging study, NMBs were not adopted widely by many ICU physicians, perhaps due to poor confidence in the validity of the results and persistent concerns regarding adverse effects of NMBs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second major randomized trial was published in 2019 (ROSE). Patients had moderate to severe ARDS, defined by a PaO<sub>2</sub>/FiO<sub>2</sub> ratio of &lt;150 mmHg with a positive end-expiratory pressure (PEEP) of ≥8 cm H<sub>2</sub>O, and were similar to those in ACURASYS except a slightly higher PEEP was used at baseline [<a href="#rid12">12</a>]. Patients were randomly assigned to receive a <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">cisatracurium</a> infusion for 48 hours but unlike ACURASYS, the control group received light sedation (Richmond Agitation-Sedation Scale of 0 or -1, or a similar score if another scale was used). Despite lower mean PEEP and FiO<sub>2</sub> requirements, cisatracurium did not lower hospital mortality (43 percent each), ventilator-free days, or rates of barotrauma compared with patients receiving light sedation but did result in more adverse cardiovascular events (2.8 versus 0.8 percent). The lack of survival benefit persisted at 6 and 12 months. Although patients receiving cisatracurium were less physically active during their hospital stay, rates of ICU-acquired weakness were no different when compared with patients on light sedation.</p><p></p><p class="bulletIndent1">Limitations of this analysis include the lack of blinding of healthcare professionals administering the agent and early cessation of the trial for reasons of futility.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of five trials (that included ACURASYS and ROSE) reported no significant mortality reduction when patients treated with NMBs were compared with patient not treated with NMBs (relative risk 0.80 95% CI 0.57-1.04) [<a href="#rid13">13</a>].</p><p></p><p>Reasons for the disparity between the results of these two trials are unclear but may relate to the differences in the degree of sedation in the control group as well as differences in PEEP strategies, use of prone positioning, and timing of NMB administration after enrollment.</p><p class="headingAnchor" id="H2842886835"><span class="h1">INHALED PULMONARY VASODILATORS</span><span class="headingEndMark"> — </span>In patients with severe ARDS who have hypoxemia that is refractory to standard therapies, several case series suggest that inhaled pulmonary vasodilators (eg, nitric oxide [NO], prostacyclin) may be used to improve oxygenation [<a href="#rid14">14-34</a>]. They may be especially helpful in patients with ARDS who also have decompensated or acute pulmonary arterial hypertension and right heart dysfunction. However, they have not been shown to reduce morbidity or mortality, a response is not guaranteed, and adverse effects may occur. (See  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults", section on 'Pulmonary vasodilators'</a>.)</p><p>The rationale for the use of inhaled pulmonary vasodilators is that they selectively dilate the vessels that perfuse well-ventilated lung zones, resulting in improved oxygenation due to better ventilation/perfusion (V/Q) matching  (<a class="graphic graphic_figure graphicRef56760" href="/z/d/graphic/56760.html" rel="external">figure 2</a>). Inhaled pulmonary vasodilators may also ameliorate the contribution of pulmonary hypertension to hypoxemia [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H971327853"><span class="h2">Choosing an agent</span><span class="headingEndMark"> — </span>Choosing among the options is usually physician- and institution-dependent. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Some clinicians choose prostacyclin since their institution may only provide prostacyclin due to its lower cost and ease of administration compared with NO while others use NO when NO is bought in bulk by their institution (often for use in the pediatric population).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other centers use an initial trial of NO (eg, 20 parts per million for one hour) to determine responsiveness; responders are continued on NO or transitioned to inhaled <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with airborne micro-organisms that need aggressive infection control, NO may also be preferred since it is associated with a less frequent need to change filters, thereby reducing infectious exposures.</p><p></p><p class="bulletIndent1">Consistent with variable use in practice, one retrospective study reported large variation across several US institutions in the use of initial inhaled pulmonary vasodilator for respiratory failure without any difference in outcomes based on inhaled vasodilator type [<a href="#rid35">35</a>]. Regardless, it is prudent that the clinicians familiarize themselves with the advantages and disadvantages of each agent and ensure that staff are adequately trained in their use. (See  <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult", section on 'Subsequent measures'</a>.)</p><p></p><p class="headingAnchor" id="H2672827462"><span class="h2">Assessing the response</span><span class="headingEndMark"> — </span>If patients respond to inhaled pulmonary vasodilators, they generally do so within the first 24 hours, so trials should be discontinued if no response is seen.</p><p>What is considered a response is unknown, but we consider an improvement in the PaO<sub>2</sub>/FiO<sub>2</sub> ratio by 10 to 20 percent or more as a significant response.</p><p>For responders, the optimal duration is unknown, but we generally try to avoid prolonged exposure (eg, more than several days), particularly when NO is administered. (See  <a class="medical medical_review" href="/z/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H899949048"><span class="h2">Efficacy and safety</span><span class="headingEndMark"> — </span>Data thus far suggest that no agent is superior to the other [<a href="#rid26">26,36,37</a>]. In a retrospective study of 239 patients with ARDS, inhaled NO and <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, a prostacyclin analogue, were associated with a similar improvement in oxygenation at four hours [<a href="#rid36">36</a>]. In addition, the proportion of patents that responded was also similar (approximately two-thirds) and there was no difference in other outcomes including mortality, duration of mechanical ventilation, or hospital length of stay.</p><p class="headingAnchor" id="H1934615977"><span class="h3">Inhaled nitric oxide</span><span class="headingEndMark"> — </span>Several meta-analyses (each with over 1200 patients) have reported that inhaled NO induced a modest, transient improvement in oxygenation, without any improvement in mortality, duration of mechanical ventilation, or ventilator-free days when compared with either placebo or conventional management [<a href="#rid17">17,18,20</a>].</p><p>However, oxygenation does not improve in all patients who receive inhaled NO [<a href="#rid14">14,23</a>]. The factors that determine responsiveness are uncertain. Retrospective cohort studies have suggested that patients without sepsis [<a href="#rid24">24</a>], patients with high baseline pulmonary vascular resistance, and patients who are PEEP-responsive may have an increased likelihood of responding to inhaled NO [<a href="#rid25">25</a>].</p><p>Adverse effects from NO include hypotension, methemoglobinemia, and renal failure. These and other potential adverse effects are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use", section on 'Adverse effects'</a>.)</p><p>Administration of NO is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8264.html" rel="external">"Inhaled nitric oxide in adults: Biology and indications for use", section on 'Administration'</a>.)</p><p class="headingAnchor" id="H1384526532"><span class="h3">Inhaled prostaglandins</span><span class="headingEndMark"> — </span>Limited data support the use of inhaled prostaglandins in patients with ARDS.</p><p class="bulletIndent1"><span class="glyph">●</span>One meta-analysis of 25 mostly nonrandomized studies reported that inhaled prostaglandins were associated with improvement in oxygenation (PaO<sub>2</sub>/FiO<sub>2</sub> ratio 39 percent higher, 95% CI 26.7-51.3 percent; PaO<sub>2</sub> 21.4 percent higher, 95% CI 12.2-30.6 percent), and a decrease in pulmonary artery pressure (-4.8 mmHg, 95% CI -6.8 to -2.8 mmHg) [<a href="#rid32">32</a>]. Systemic hypotension occurred in 17 percent and mortality could not be assessed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several case series have shown similar results in response to inhaled prostacyclin (ie, <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>) without an impact on mortality [<a href="#rid26">26-34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preliminary data in patients with ARDS and concomitant pulmonary hypertension reported that inhaled <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a>, a prostacyclin analog, improved oxygenation without adverse effects on lung mechanics or systemic hemodynamics [<a href="#rid34">34</a>].</p><p></p><p>The major advantage of inhaled prostacyclin compared with inhaled NO is that it does not require sophisticated equipment for administration. Each institution should develop their own protocol for administration. A suggested dosing protocol for <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> is available in Lexicomp. All dosing should be prescribed by a provider knowledgeable regarding this agent. We avoid abrupt discontinuation to prevent rebound pulmonary hypertension, and when cessation is desired, we attempt to wean it slowly (eg, 10 ng/kg/minute every hour)</p><p>Clinical experience with inhaled prostacyclin for patients with ARDS suggests that adverse effects are infrequent, but side effects such as systemic hypotension, chest pain, bleeding, flushing, headache, nausea, and vomiting have been described [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H3066443737"><span class="h1">GLUCOCORTICOIDS</span><span class="headingEndMark"> — </span>Our approach to the use of systemic glucocorticoid therapy in patients with ARDS is discussed in the sections below.</p><p class="headingAnchor" id="H3876798028"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Glucocorticoids can be administered in the following patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with ARDS whose underlying condition meets requirements for systemic glucocorticoid therapy</strong> – This includes the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ARDS that has been precipitated by a steroid-responsive process (eg, acute eosinophilic pneumonia, organizing pneumonia). (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ARDS associated with refractory septic shock. (See  <a class="medical medical_review" href="/z/d/html/1654.html" rel="external">"Glucocorticoid therapy in septic shock in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ARDS associated with coronavirus disease 2019 (COVID-19). (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ARDS associated with community-acquired pneumonia. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Adjunctive glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with moderate to severe ARDS who are relatively early in the disease course who fail standard therapies</strong> – We recommend glucocorticoid therapy for most patients who are relatively early in the disease course (within 14 days of onset) who have persistent or refractory moderate to severe ARDS (partial arterial pressure of oxygen/fraction of inspired oxygen [PaO<sub>2</sub>/FiO<sub>2</sub>] ratio &lt;200) despite initial management with standard therapies, including low tidal volume ventilation. This approach is based on available clinical trial data that report a probable mortality benefit  (<a class="graphic graphic_figure graphicRef121523" href="/z/d/graphic/121523.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent1">Based on these data, the Society of Critical Care Medicine/European Society of Intensive Care Medicine (SCCM/ESICM) issued a conditional recommendation favoring glucocorticoids in patients with early moderate to severe ARDS [<a href="#rid38">38</a>].</p><p></p><p class="headingAnchor" id="H2088026314"><span class="h3">Regimens</span><span class="headingEndMark"> — </span>When glucocorticoids are used for other steroid-responsive conditions that are associated with ARDS, we follow the protocol typically used for that etiology. (See <a class="local">'Indications'</a> above.)</p><p>When glucocorticoid therapy is used for ARDS itself, commonly used regimens include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">Methylprednisolone</a> 1 mg/kg/day in divided doses for 14 days, followed by a taper for a total of 21 to 28 days (using ideal body weight dosing) [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> 20 mg IV once daily for five days, then 10 mg once daily for five days [<a href="#rid39">39</a>].</p><p></p><p>The agents used (eg, <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>) and dosing regimens varied somewhat in the available clinical trials. The efficacy of the different regimens appears to be generally similar [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H1905870884"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The available evidence regarding the efficacy and adverse effects of glucocorticoid therapy in patients with ARDS is summarized in the figure  (<a class="graphic graphic_figure graphicRef121523" href="/z/d/graphic/121523.html" rel="external">figure 3</a>) [<a href="#rid38">38,40-51</a>]. The major adverse effects of systemic glucocorticoids are described in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>An important limitation of the data on glucocorticoid therapy in ARDS is that low tidal volume ventilation (for example, as implemented by the ARDS Network) was not consistently performed or not documented in the majority of clinical trials. In the three trials that documented use of low tidal volume strategies, two trials reported similar mortality rates among patients receiving glucocorticoids compared with placebo [<a href="#rid41">41,43</a>], while the third trial reported lower mortality with glucocorticoids [<a href="#rid39">39</a>]. However, when taken together, the data suggest a probable mortality benefit, as shown in panel D of the figure  (<a class="graphic graphic_figure graphicRef121523" href="/z/d/graphic/121523.html" rel="external">figure 3</a>).</p><p>Ongoing trials may shed light on issues including dosing, timing, agent selection, and which patients are most likely to benefit (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02819453%3Fterm%3DARDS%26rank%3D199&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOEHkWhnBEwSHrSPas%2FSpT3jdjyHd3IhTbv%2BV6%2Bf4tIzbhE531vegqtke3xxdCDSvY%3D&amp;TOPIC_ID=1641" target="_blank">NCT02819453</a>).</p><p class="headingAnchor" id="H4111291173"><span class="h2">Avoidance of glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are generally <strong>not</strong> administered in the following patients:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with less severe ARDS</strong> – We do not routinely use glucocorticoids in patients who have less severe ARDS (PaO<sub>2</sub>/FiO<sub>2</sub> ratio ≥200).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients late in the disease course</strong> – We generally avoid glucocorticoid use in patients who have persistent ARDS beyond 14 days based upon limited data suggesting glucocorticoids may be harmful in this setting. In the available clinical trials, the mortality benefit of glucocorticoid therapy was seen only among patients randomized before day 14 after ARDS onset. Among patients randomized on or after day 14, glucocorticoid therapy appeared to increase mortality, as shown in panel C of the figure  (<a class="graphic graphic_figure graphicRef121523" href="/z/d/graphic/121523.html" rel="external">figure 3</a>). However, in patients with persistent/refractory ARDS beyond 14 days, it may be reasonable to pursue additional diagnostic evaluation (eg, bronchoscopy, lung biopsy) for other possible etiologies, for which glucocorticoid therapy may be appropriate (eg, organizing pneumonia). (See  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with influenza infection</strong> – We generally avoid glucocorticoids in patients with ARDS secondary to influenza because glucocorticoid use may be associated with worse outcomes in such patients [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">SUPPORTIVE CARE</span><span class="headingEndMark"> — </span>A minority of patients with ARDS die from respiratory failure alone [<a href="#rid53">53-56</a>]. More commonly, such patients succumb to the primary illness underlying ARDS or to secondary complications. Supportive care is targeted at reducing these complications while therapy targeted at ARDS and the underlying etiology is ongoing. These issues are largely discussed in the linked sections below.</p><p class="headingAnchor" id="H3"><span class="h2">Sedation</span><span class="headingEndMark"> — </span>In patients with ARDS, we avoid excessive sedation and use validated scales to achieve light sedation. The use of sedative-analgesic medications in critically ill patients, including patients with ARDS, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a> and  <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/2888.html" rel="external">"Pain control in the critically ill adult patient"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Hemodynamic monitoring</span><span class="headingEndMark"> — </span>Patients with ARDS are monitored using vital signs and telemetry. Often patients additionally require invasive monitoring with an arterial line and central venous catheter (CVC). Indications for invasive monitoring are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8174.html" rel="external">"Intra-arterial catheterization for invasive monitoring: Indications, insertion techniques, and interpretation"</a> and  <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">"Central venous access in adults: General principles"</a>.)</p><p>Routine use of pulmonary artery catheters has fallen out of favor since data do not support this practice [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a>.)</p><p>Point-of-care ultrasonography to monitor hemodynamics are being increasingly used to guide fluid management in patients with shock and are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/107337.html" rel="external">"Novel tools for hemodynamic monitoring in critically ill patients with shock"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Nutritional support</span><span class="headingEndMark"> — </span>Patients with ARDS are intensely catabolic and nutritional support may help to offset catabolic losses and modulate the metabolic response to stress, mitigate oxidative cellular injury, and promote beneficial immune responses [<a href="#rid58">58</a>]. Further details regarding nutrition in critically ill patients are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a> and  <a class="medical medical_review" href="/z/d/html/1605.html" rel="external">"Nutrition support in intubated critically ill adult patients: Enteral nutrition"</a> and  <a class="medical medical_review" href="/z/d/html/1626.html" rel="external">"Nutrition support in intubated critically ill adult patients: Parenteral nutrition"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Glucose control</span><span class="headingEndMark"> — </span>The approach to glucose control in patients with ARDS is extrapolated from trials that enrolled patients with critical illness, including ARDS. Glucose management and target ranges for acceptable blood sugar control are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Nosocomial pneumonia prevention and management</span><span class="headingEndMark"> — </span>Nosocomial pneumonia is common among patients with ARDS [<a href="#rid59">59</a>], with the first episode occurring within a median of 10 days [<a href="#rid60">60</a>]. The impact of nosocomial pneumonia on morbidity and mortality is unclear [<a href="#rid60">60</a>]. We follow standard guidelines recommended for the general population of mechanically ventilated patients to help prevent, diagnose, and treat ventilator-associated pneumonia [<a href="#rid61">61,62</a>], the details of which are discussed separately (See  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1656.html" rel="external">"The ventilator circuit"</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Venous thromboembolism prophylaxis</span><span class="headingEndMark"> — </span>The frequency of deep venous thrombosis and pulmonary embolism in patients with ARDS is unknown, but the risk is high, despite prophylaxis. These patients often have multiple risk factors for venous thrombosis, including prolonged immobility, trauma, and predisposing illnesses, such as sepsis, obesity, and malignancy. Thus, all patients with ARDS require some form of thromboprophylaxis, the details of which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Stress ulcer prophylaxis</span><span class="headingEndMark"> — </span>Patients with ARDS requiring prolonged mechanical ventilation are at high risk for gastrointestinal bleeding and require stress ulcer prophylaxis. Prophylaxis and management of stress ulcers are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">"Stress ulcers in the intensive care unit: Diagnosis, management, and prevention"</a>.)</p><p class="headingAnchor" id="H1344395444"><span class="h2">Venous access</span><span class="headingEndMark"> — </span>While peripheral venous access is the fastest form of access for the initial management of critically ill patients with ARDS, CVCs have additional advantages. As examples, CVCs can be used to administer vasopressors, measure central venous pressure and draw blood for laboratory testing. The indications for central line placement, technique, and complications of peripheral and central access are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13824.html" rel="external">"Peripheral venous access in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">"Central venous access in adults: General principles"</a> and  <a class="medical medical_review" href="/z/d/html/15672.html" rel="external">"Placement of jugular venous catheters"</a> and  <a class="medical medical_review" href="/z/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a>.)</p><p class="headingAnchor" id="H1855758801"><span class="h2">Mucolytics</span><span class="headingEndMark"> — </span>Evidence suggests that there is no role for the routine administration of mucolytics in patients with ARDS [<a href="#rid63">63,64</a>].</p><p class="headingAnchor" id="H838355013"><span class="h2">Fever control</span><span class="headingEndMark"> — </span>Critically ill patients with ARDS frequently develop fever. Management of fever in patients with ARDS is similar to that in other critically ill patients who are admitted to the intensive care unit (ICU). Further details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1624.html" rel="external">"Fever in the intensive care unit"</a>.)</p><p class="headingAnchor" id="H3528743595"><span class="h2">Blood product transfusion</span><span class="headingEndMark"> — </span>Blood products are commonly administered to patients with ARDS. Data, including target hemoglobin levels used in patients with ARDS, are extrapolated from critically ill patients in the ICU. Further details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1615.html" rel="external">"Use of blood products in the critically ill"</a>.)</p><p class="headingAnchor" id="H1677376958"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117301.html" rel="external">"Society guideline links: Acute respiratory failure and acute respiratory distress syndrome in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/119032.html" rel="external">"Society guideline links: Assessment of oxygenation and gas exchange"</a>.)</p><p></p><p class="headingAnchor" id="H1986202"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17029.html" rel="external">"Patient education: Acute respiratory distress syndrome (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluid management</strong> – In patients with acute respiratory distress syndrome (ARDS), we suggest a conservative rather than liberal fluid management strategy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Conservative fluid management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The goal is to minimize or eliminate a positive fluid balance. It is reasonable to target a central venous pressure of &lt;4 mmHg. Diuretics may need to be administered to achieve this goal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The rationale for this strategy is based upon the increased risk of pulmonary edema in patients with ARDS and data that suggest improved oxygenation with a conservative approach, although no clear mortality benefit has been shown. (See <a class="local">'Goal and fluid choice'</a> above and <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paralysis</strong> – In patients with ARDS, we do <strong>not routinely</strong> administer neuromuscular blockers (NMBs). This approach is based upon a lack of robust evidence to support clinically meaningful benefit from NMBs in this population and their potential for harm. We reserve their use for patients with ARDS who have severe hypoxemia refractory to standard therapies and patients with severe ventilator dyssynchrony that is refractory to ventilator adjustment and sedation  (<a class="graphic graphic_table graphicRef75880" href="/z/d/graphic/75880.html" rel="external">table 1</a>). (See <a class="local">'Paralysis (neuromuscular blockade)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhaled pulmonary vasodilators</strong> – In patients with ARDS, we do <strong>not routinely</strong> administer inhaled pulmonary vasodilators. We reserve their use for patients with ARDS who have severe hypoxemia refractory to standard therapies or patients with ARDS who also have concomitant decompensated acute pulmonary arterial hypertension and right heart dysfunction. (See <a class="local">'Inhaled pulmonary vasodilators'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid administration</strong> – Our approach to the use of systemic glucocorticoid therapy in ARDS is as follows (see <a class="local">'Glucocorticoids'</a> above):</p><p></p><p class="bulletIndent1">Patients in whom we administer systemic glucocorticoids include the following (see <a class="local">'Indications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with ARDS whose underlying condition meets requirements for systemic glucocorticoid therapy</strong> – This includes:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>A steroid-responsive process (eg, acute eosinophilic pneumonia, organizing pneumonia). (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/4332.html" rel="external">"Cryptogenic organizing pneumonia", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Refractory septic shock. (See  <a class="medical medical_review" href="/z/d/html/1654.html" rel="external">"Glucocorticoid therapy in septic shock in adults"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>COVID-19. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Community-acquired pneumonia. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Adjunctive glucocorticoids'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early moderate to severe ARDS refractory to standard therapy</strong> – In addition, for most patients who are relatively early in the disease course (within 14 days of onset) who have persistent or refractory moderate to severe ARDS (partial arterial pressure of oxygen/fraction of inspired oxygen [PaO<sub>2</sub>/FiO<sub>2</sub>] ratio &lt;200) despite initial management with standard therapies, including low tidal volume ventilation, we recommend glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2">Several randomized trials and meta-analyses support the efficacy and safety of glucocorticoids in this setting  (<a class="graphic graphic_figure graphicRef121523" href="/z/d/graphic/121523.html" rel="external">figure 3</a>). Future studies may shed light on which patients are likely to benefit from glucocorticoid treatment and which are likely to be harmed.</p><p></p><p class="bulletIndent2">A typical regimen for this population is <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> 1 mg/kg/day in divided doses for 14 days followed by a taper for a total of 21 to 28 days or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 20 mg IV once daily for five days followed by 10 mg once daily for five days. (See <a class="local">'Regimens'</a> above.)</p><p></p><p class="bulletIndent1">Patients in whom we do <strong>not</strong> administer systemic glucocorticoids include the following (see <a class="local">'Avoidance of glucocorticoids'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mild or late ARDS</strong> – We do <strong>not</strong> routinely use glucocorticoids in patients who have less severe ARDS and we avoid their use in patients who have persistent ARDS beyond 14 days based upon limited data suggesting glucocorticoids may be harmful in this setting  (<a class="graphic graphic_figure graphicRef121523" href="/z/d/graphic/121523.html" rel="external">figure 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Influenza-related ARDS</strong> – We do <strong>not</strong> administer glucocorticoid therapy in influenza-related ARDS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive care</strong> – Key components of supportive care for patients with ARDS include the following (see <a class="local">'Supportive care'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Appropriate use of sedatives. (See  <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a> and  <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Careful hemodynamic management. (See  <a class="medical medical_review" href="/z/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/107337.html" rel="external">"Novel tools for hemodynamic monitoring in critically ill patients with shock"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nutritional support. (See  <a class="medical medical_review" href="/z/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Control of blood glucose. (See  <a class="medical medical_review" href="/z/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prevention and treatment of nosocomial pneumonia. (See  <a class="medical medical_review" href="/z/d/html/6995.html" rel="external">"Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1635.html" rel="external">"Clinical presentation and diagnostic evaluation of ventilator-associated pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1656.html" rel="external">"The ventilator circuit"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prophylaxis against venous thromboembolism. (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prophylaxis against gastrointestinal bleeding. (See  <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">"Stress ulcers in the intensive care unit: Diagnosis, management, and prevention"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Venous access. (See  <a class="medical medical_review" href="/z/d/html/13824.html" rel="external">"Peripheral venous access in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">"Central venous access in adults: General principles"</a> and  <a class="medical medical_review" href="/z/d/html/15672.html" rel="external">"Placement of jugular venous catheters"</a> and  <a class="medical medical_review" href="/z/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15671.html" rel="external">"Routine care and maintenance of intravenous devices"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fever control. (See  <a class="medical medical_review" href="/z/d/html/1624.html" rel="external">"Fever in the intensive care unit"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Blood transfusion. (See  <a class="medical medical_review" href="/z/d/html/1615.html" rel="external">"Use of blood products in the critically ill"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564.</a></li><li><a class="nounderline abstract_t">Grissom CK, Hirshberg EL, Dickerson JB, et al. Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*. Crit Care Med 2015; 43:288.</a></li><li><a class="nounderline abstract_t">Mikkelsen ME, Christie JD, Lanken PN, et al. The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med 2012; 185:1307.</a></li><li><a class="nounderline abstract_t">Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med 2017; 43:155.</a></li><li><a class="nounderline abstract_t">Mitchell JP, Schuller D, Calandrino FS, Schuster DP. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis 1992; 145:990.</a></li><li><a class="nounderline abstract_t">Simmons RS, Berdine GG, Seidenfeld JJ, et al. Fluid balance and the adult respiratory distress syndrome. Am Rev Respir Dis 1987; 135:924.</a></li><li><a class="nounderline abstract_t">Humphrey H, Hall J, Sznajder I, et al. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest 1990; 97:1176.</a></li><li><a class="nounderline abstract_t">Silversides JA, Fitzgerald E, Manickavasagam US, et al. Deresuscitation of Patients With Iatrogenic Fluid Overload Is Associated With Reduced Mortality in Critical Illness. Crit Care Med 2018; 46:1600.</a></li><li><a class="nounderline abstract_t">Semler MW, Wheeler AP, Thompson BT, et al. Impact of Initial Central Venous Pressure on Outcomes of Conservative Versus Liberal Fluid Management in Acute Respiratory Distress Syndrome. Crit Care Med 2016; 44:782.</a></li><li><a class="nounderline abstract_t">Liu X, Jiang Y, Jia X, et al. Identification of distinct clinical phenotypes of acute respiratory distress syndrome with differential responses to treatment. Crit Care 2021; 25:320.</a></li><li><a class="nounderline abstract_t">Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome. N Engl J Med 2019; 380:1997.</a></li><li><a class="nounderline abstract_t">Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med 2023; 49:727.</a></li><li><a class="nounderline abstract_t">Rossaint R, Falke KJ, López F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399.</a></li><li><a class="nounderline abstract_t">Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291:1603.</a></li><li><a class="nounderline abstract_t">Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26:15.</a></li><li><a class="nounderline abstract_t">Adhikari NK, Burns KE, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007; 334:779.</a></li><li><a class="nounderline abstract_t">Afshari A, Brok J, Møller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth Analg 2011; 112:1411.</a></li><li><a class="nounderline abstract_t">Adhikari NK, Dellinger RP, Lundin S, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis. Crit Care Med 2014; 42:404.</a></li><li><a class="nounderline abstract_t">Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev 2016; :CD002787.</a></li><li><a class="nounderline abstract_t">Karam O, Gebistorf F, Wetterslev J, Afshari A. The effect of inhaled nitric oxide in acute respiratory distress syndrome in children and adults: a Cochrane Systematic Review with trial sequential analysis. Anaesthesia 2017; 72:106.</a></li><li><a class="nounderline abstract_t">Pipeling MR, Fan E. Therapies for refractory hypoxemia in acute respiratory distress syndrome. JAMA 2010; 304:2521.</a></li><li><a class="nounderline abstract_t">Rossaint R, Gerlach H, Schmidt-Ruhnke H, et al. Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995; 107:1107.</a></li><li><a class="nounderline abstract_t">Manktelow C, Bigatello LM, Hess D, Hurford WE. Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1997; 87:297.</a></li><li><a class="nounderline abstract_t">Puybasset L, Rouby JJ, Mourgeon E, et al. Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure. Am J Respir Crit Care Med 1995; 152:318.</a></li><li><a class="nounderline abstract_t">Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671.</a></li><li><a class="nounderline abstract_t">Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153:991.</a></li><li><a class="nounderline abstract_t">Ferring M, Vincent JL. Is outcome from ARDS related to the severity of respiratory failure? Eur Respir J 1997; 10:1297.</a></li><li><a class="nounderline abstract_t">Royston D. Inhalational agents for pulmonary hypertension. Lancet 1993; 342:941.</a></li><li><a class="nounderline abstract_t">van Heerden PV, Barden A, Michalopoulos N, et al. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000; 117:819.</a></li><li><a class="nounderline abstract_t">Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med 2001; 29:57.</a></li><li><a class="nounderline abstract_t">Fuller BM, Mohr NM, Skrupky L, et al. The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis. Chest 2015; 147:1510.</a></li><li><a class="nounderline abstract_t">Afshari A, Brok J, Møller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev 2010; :CD007733.</a></li><li><a class="nounderline abstract_t">Sawheny E, Ellis AL, Kinasewitz GT. Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS. Chest 2013; 144:55.</a></li><li><a class="nounderline abstract_t">Bosch NA, Law AC, Vail EA, et al. Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation. Chest 2022; 162:1287.</a></li><li><a class="nounderline abstract_t">Buckley MS, Agarwal SK, Garcia-Orr R, et al. Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults. J Intensive Care Med 2021; 36:466.</a></li><li><a class="nounderline abstract_t">Ammar MA, Bauer SR, Bass SN, et al. Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS. Ann Pharmacother 2015; 49:1105.</a></li><li><a class="nounderline abstract_t">Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 2017; 43:1751.</a></li><li><a class="nounderline abstract_t">Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020; 8:267.</a></li><li><a class="nounderline abstract_t">Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database Syst Rev 2019; 7:CD004477.</a></li><li><a class="nounderline abstract_t">Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671.</a></li><li><a class="nounderline abstract_t">Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131:954.</a></li><li><a class="nounderline abstract_t">Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 2016; 20:329.</a></li><li><a class="nounderline abstract_t">Rezk, NA, Ibrahim, AM. . Effects of methylprednisolone in early ARDS. Egyptian Journal of Chest Diseases and Tuberculosis 2013; 62:167.</a></li><li><a class="nounderline abstract_t">Sabry, NA, Omar, EE . Corticosteroids and ICU course of community acqured pneumonia in Egyptian settings. Pharmacology &amp; Pharmacy 2011; 2:73.</a></li><li><a class="nounderline abstract_t">Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242.</a></li><li><a class="nounderline abstract_t">Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998; 280:159.</a></li><li><a class="nounderline abstract_t">Annane D, Sébille V, Bellissant E, Ger-Inf-05 Study Group. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006; 34:22.</a></li><li><a class="nounderline abstract_t">Meduri GU, Bridges L, Shih MC, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med 2016; 42:829.</a></li><li><a class="nounderline abstract_t">Yoshihiro S, Hongo T, Ohki S, et al. Steroid treatment in patients with acute respiratory distress syndrome: a systematic review and network meta-analysis. J Anesth 2022; 36:107.</a></li><li><a class="nounderline abstract_t">Lv H, Dai L, Lu J, et al. Efficacy and safety of methylprednisolone against acute respiratory distress syndrome: A systematic review and meta-analysis. Medicine (Baltimore) 2021; 100:e25408.</a></li><li><a class="nounderline abstract_t">Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2016; 3:CD010406.</a></li><li><a class="nounderline abstract_t">Stapleton RD, Wang BM, Hudson LD, et al. Causes and timing of death in patients with ARDS. Chest 2005; 128:525.</a></li><li><a class="nounderline abstract_t">Montgomery AB, Stager MA, Carrico CJ, Hudson LD. Causes of mortality in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1985; 132:485.</a></li><li><a class="nounderline abstract_t">Suchyta MR, Clemmer TP, Elliott CG, et al. The adult respiratory distress syndrome. A report of survival and modifying factors. Chest 1992; 101:1074.</a></li><li><a class="nounderline abstract_t">Doyle RL, Szaflarski N, Modin GW, et al. Identification of patients with acute lung injury. Predictors of mortality. Am J Respir Crit Care Med 1995; 152:1818.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213.</a></li><li><a class="nounderline abstract_t">Martindale RG, McClave SA, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care Med 2009; 37:1757.</a></li><li><a class="nounderline abstract_t">Delclaux C, Roupie E, Blot F, et al. Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis. Am J Respir Crit Care Med 1997; 156:1092.</a></li><li><a class="nounderline abstract_t">Zampieri FG, Póvoa P, Salluh JI, et al. Lower Respiratory Tract Infection and Short-Term Outcome in Patients With Acute Respiratory Distress Syndrome. J Intensive Care Med 2020; 35:588.</a></li><li><a class="nounderline abstract_t">Sinuff T, Muscedere J, Cook DJ, et al. Implementation of clinical practice guidelines for ventilator-associated pneumonia: a multicenter prospective study. Crit Care Med 2013; 41:15.</a></li><li><a class="nounderline abstract_t">Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</a></li><li><a class="nounderline abstract_t">Icard BL, Rubio E. The role of mucoactive agents in the mechanically ventilated patient: a review of the literature. Expert Rev Respir Med 2017; 11:807.</a></li><li><a class="nounderline abstract_t">Anand R, McAuley DF, Blackwood B, et al. Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis. Thorax 2020; 75:623.</a></li></ol></div><div id="topicVersionRevision">Topic 1641 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714767" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comparison of two fluid-management strategies in acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25599463" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fluid management with a simplified conservative protocol for the acute respiratory distress syndrome*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492988" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27734109" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586077" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3565940" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fluid balance and the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2100979" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985214" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Deresuscitation of Patients With Iatrogenic Fluid Overload Is Associated With Reduced Mortality in Critical Illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26741580" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of Initial Central Venous Pressure on Outcomes of Conservative Versus Liberal Fluid Management in Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34461969" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Identification of distinct clinical phenotypes of acute respiratory distress syndrome with differential responses to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843245" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Neuromuscular blockers in early acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31112383" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37326646" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8357359" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Inhaled nitric oxide for the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15069048" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9428538" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383982" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21372277" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24132038" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27347773" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27762438" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The effect of inhaled nitric oxide in acute respiratory distress syndrome in children and adults: a Cochrane Systematic Review with trial sequential analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21139113" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Therapies for refractory hypoxemia in acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7705124" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Efficacy of inhaled nitric oxide in patients with severe ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9286894" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599840" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8970353" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630585" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9192932" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Is outcome from ARDS related to the severity of respiratory failure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8105208" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inhalational agents for pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10713012" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176161" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25742022" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20687093" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370599" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Iloprost improves gas exchange in patients with pulmonary hypertension and ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35952768" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32133901" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26187741" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28940011" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32043986" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31334568" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pharmacological agents for adults with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625008" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17426195" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27741949" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of methylprednisolone in early ARDS</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Corticosteroids and ICU course of community acqured pneumonia in Egyptian settings</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557131" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669790" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16374152" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26508525" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34757498" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Steroid treatment in patients with acute respiratory distress syndrome: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33832136" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and safety of methylprednisolone against acute respiratory distress syndrome: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26950335" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Corticosteroids as adjunctive therapy in the treatment of influenza.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16100134" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Causes and timing of death in patients with ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4037521" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Causes of mortality in patients with the adult respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1555423" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The adult respiratory distress syndrome. A report of survival and modifying factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8520742" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Identification of patients with acute lung injury. Predictors of mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714768" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19373044" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9351607" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Lower respiratory tract colonization and infection during severe acute respiratory distress syndrome: incidence and diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29699468" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Lower Respiratory Tract Infection and Short-Term Outcome in Patients With Acute Respiratory Distress Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23222254" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Implementation of clinical practice guidelines for ventilator-associated pneumonia: a multicenter prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418577" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28737047" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The role of mucoactive agents in the mechanically ventilated patient: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32513777" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
